Repurposing FDA-Approved Drugs for Treatment of 2019-nCoV-induced Disease

点击翻译按钮获取中文摘要

SARS/CoV-2 was recently identified as the cause of the outbreak of pneumonia first detected in Wuhan, China in December 2019. Current efforts are focused on containment and separation of infected individuals, with no registered drugs for the treatment of COVID-19. Hence, drugs that have been registered for the treatment of other coronavirus conditions might be used (off-label) in an attempt to save the lives of COVID-19 patients. As development of vaccines and drugs for prevention and treatment of SARS-CoV-2 infection have been brought to priority status by WHO and governments, numerous drug studies are moving forward. Drug repurposing is defined as the application of known drugs to new indications. This approach is attractive, as repurposed drugs have already passed toxicity trials. Therefore, we aim to screen clinically approved drugs either as single or pair combinations for the therapeutic development of antiviral and anti-inflammatory agents to control and treat COVID-19 disease. We strongly anticipate the data generated will identify novel single or synergistic drug pairs, lead to detailed pre-clinical evaluation and provide the impetus for rapid progress to clinical trials or compassionate use in extreme cases.